NCI Eyes Some Budget Gains for FY2007

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Congress finally resolved the current federal budget in mid-February, 4 months after fiscal year (FY) 2007 began, and raised the National Institutes of Health's funding to $28.9 billion, an increase of $619.5 million (2%) over its FY2006 appropriations.

BETHESDA, Maryland—Congress finally resolved the current federal budget in mid-February, 4 months after fiscal year (FY) 2007 began, and raised the National Institutes of Health's funding to $28.9 billion, an increase of $619.5 million (2%) over its FY2006 appropriations. Although Congress kept the National Cancer Institute's budget at $4.79 billion, the Institute gained approximately $42.8 million in additional dollars because it will not have to contribute to the NIH common fund this year. These dollar gains plus money from other sources should increase NCI's available dollars by $46 million, NCI director John E. Niederhuber, MD, said at a meeting of the National Cancer Advisory Board.

The money should enable NCI to provide $2.022 billion to fund 5,188 research project grants in FY2007, 16 more than in FY2006, he said. Noncompeting grants will fall to 3,878, a decrease of 14 from last fiscal year, and these grants will have no inflationary adjustments built into them. Competing grants will rise to 1,310, an increase of 30.

In his proposed budget for FY2008, President Bush asked Congress to provide NIH $28.9 billion and NCI $4.782 billion, decreases of $511 million and $11 million, respectively, from their newly approved FY2007 funding.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content